Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05336786
PHASE3

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Sponsor: Thomas Jefferson University

View on ClinicalTrials.gov

Summary

This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2022-06-15

Completion Date

2026-05-26

Last Updated

2025-09-04

Healthy Volunteers

No

Interventions

DRUG

Perflutren Lipid Microspheres

Given IV

PROCEDURE

Ultrasound

Undergo ultrasound

Locations (2)

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Amsterdam University Medical Centers

Amsterdam, Netherlands